Finch Therapeutics Faces Nasdaq Delisting and Patent Litigation
Company Announcements

Finch Therapeutics Faces Nasdaq Delisting and Patent Litigation

Finch Therapeutics Group (FNCH) has released an update.

Finch Therapeutics Group, Inc. faces a challenge as Nasdaq has flagged it as a “public shell,” questioning the legitimacy of its operational business and suggesting a delisting. While the company contests this, seeking an appeal that delays any immediate delisting consequence, uncertainty looms over its future on the exchange. Additionally, ongoing patent litigation with Rebiotix Inc. and Ferring Pharmaceuticals further complicates Finch’s situation, with the trial now postponed to August 2024.

For further insights into FNCH stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskFinch Therapeutics Group to Delist from Nasdaq
TheFlyFinch Therapeutics announces Nasdaq delisting, SEC deregistration
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App